Sample reports

What we ship, on real IP.

Three sanitised but real Patent Radar reports across pharma, ophthalmics, and trademark monitoring. The shape is what you can expect when your portfolio is under monitor. Every chart is a draft for legal review.

High confidencePharma · US

Niravaribx 100 mg capsule reads on US 11,091,459

Acuity Pharmaceuticals plc · matched against Niraparib salt and crystalline forms thereof (owner: Tesaro / GSK) · claims hit 4 of 12

Rationale

Generic ANDA filing discloses an XRPD fingerprint and excipient profile that read directly on claim 1 limitations [1.a] through [1.d].

Top evidence

“Active ingredient is the tosylate monohydrate of compound A in a stable crystalline form, with XRPD peaks at 7.5°, 15.2°, and 22.7° (Cu Kα).”
fda.gov / accessdata.fda.gov

Key findings

All four limitations of claim 1 read on the ANDA's chemical and physical fingerprint
XRPD pattern matches the patented Form I precisely
Same indication: maintenance treatment of recurrent epithelial ovarian cancer

Draft prepared by Patent Radar for legal review only.Run this on your portfolio →

High confidenceOphthalmics · EU

Lotenano-OD ophthalmic suspension reads on EP 3,194,019

Vista Ophthalmics SAS · matched against Loteprednol nanoparticle ophthalmic formulation (owner: Bausch + Lomb) · claims hit 3 of 8

Rationale

EMA EPAR and sponsor press release disclose 200 nm chitosan-coated nanoparticle delivery, matching claim 1 elements [a] through [c].

Top evidence

“Active substance is dispersed as chitosan-coated nanoparticles of mean size 192 ± 18 nm, formulated as a sterile aqueous suspension.”
ema.europa.eu

Key findings

Nanoparticle size (192 ± 18 nm) falls within the claimed 150 to 250 nm range
Chitosan coating layer disclosed in the EMA EPAR maps to limitation [b]
Formulation strength and excipient profile read on dependent claims 4 and 7

Draft prepared by Patent Radar for legal review only.Run this on your portfolio →

Medium confidenceTrademark · EU + US

RadarSweep.app, beta release reads on EM 018234567

RadarSweep Inc. · matched against RADARSWEEP figurative mark (classes 9 + 42) (owner: Drug Landscape Ltd) · claims hit Identical word mark, similar logo, class 9

Rationale

App Store listing uses an identical word mark in class 9 (downloadable software) and a confusingly similar figurative element. Likelihood of confusion is high under Sleekcraft factors.

Top evidence

“RadarSweep, your patent monitor in your pocket. Free for the first 30 days.”
apps.apple.com

Key findings

Identical wordmark in identical Nice class 9 (downloadable software)
Figurative element shares the central dot + sweeping arc motif of the registered mark
Domain registered three months after RADARSWEEP filing went public, suggesting awareness

Draft prepared by Patent Radar for legal review only.Run this on your portfolio →

Want a report like this on your portfolio?

Send us up to 5 of your granted patents or registered trademarks. We'll have a first-pass report back within 48 hours. No commitment.

Start a free audit →